| Full text | |
| Author(s): Show less - |
da Silva, Karina Costa
;
Lima, Irla Santos
;
Santos, Cleonice Creusa dos
;
Nonaka, Carolina Kymie Vasques
;
Souza, Bruno Solano de Freitas
;
David, Jorge Mauricio
;
Ulrich, Henning
;
Nascimento, Ravena Pereira do
;
Costa, Maria de Fatima Dias
;
dos Santos, Balbino Lino
;
Costa, Silvia Lima
Total Authors: 11
|
| Document type: | Journal article |
| Source: | Molecules; v. 30, n. 1, p. 15-pg., 2025-01-01. |
| Abstract | |
Glioblastomas (GBM) are malignant tumours with poor prognosis. Treatment involves chemotherapy and/or radiotherapy; however, there is currently no standard treatment for recurrence, and prognosis remains unfavourable. Inflammatory mediators and microRNAs (miRNAs) influence the aggressiveness of GBM, being involved in the communication with the cells of the tumour parenchyma, including microglia/macrophages, and maintaining an immunosuppressive microenvironment. Hence, the modulation of miRNAs and inflammatory factors may improve GBM treatments. In this study, we investigated the effects of agathisflavone, a biflavonoid purified from Cenostigma pyramidale (Tul.), on the growth and migration of GBM cells, on the expression of inflammatory cytokines and microRNAs, as well on the response of microglia. Agathisflavone (5-30 mu M) induced a dose- and time-dependent reduction in the viability of both human GL-15 and rat C6 cells, as determined by the MTT test, and reduced cell migration, as determined by cell scratch assay. RT-qPCR analysis revealed that agathisflavone (5 mu M) down-regulated the expression of miR-125b and miR-155 in the secretome derived from GL-15 cells, which was associated with upregulation of the mRNA expression of IL-6 and arginase-1 immunoregulatory factors. Exposure of human microglia/macrophage to the secretome from GL-15 GMB cells modulated proliferation and morphology, effects that were modulated by agathisflavone treatment. These results demonstrate the effect of flavonoids on the growth of GBM cells, which impacts cells in the microenvironment and can be considered for preclinical studies for adjuvant treatments. (AU) | |
| FAPESP's process: | 23/17147-6 - Treatment of chemoresistant human glioblastoma cells with DNA aptamers for the development of new adjuvant therapies |
| Grantee: | Alexander Henning Ulrich |
| Support Opportunities: | Regular Research Grants |